Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
Key Highlights
- ➤Spruce will present MPS IIIB natural history data October 15, 2026
- ➤Study 250-902 tracks cognition, motor, communication, and adaptive disease progression
- ➤Tralesinidase alfa remains in late-stage development for MPS IIIB
- ➤TA-ERT has FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations
Expert Statements
Ilyas Okur, Professor of Pediatrics and Pediatric Metabolism Specialist, Gazi University Faculty of Medicine
“In-depth analyses of cognition, motor, communication, and adaptive natural history disease course in participants with MPS IIIB”
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55(th) Child Neurology Society Annual Meeting
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenuated Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 55(th )Child Neurology Society (CNS) Annual Meeting , taking place October 14–17, 2026, in Montréal, Québec, Canada. The poster will be available on the Spruce Biosciences website following the presentation.
Get started
Create a free account to read the full story.